SCHEMBL4092268

SCHEMBL4092268

c1ccc(Cc2nc(N3CCCCC3)c3ccccc3n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.63
TSHR P16473 3/20 0.63
GLA P06280 1/20 0.63
HSD17B10 Q99714 1/20 0.63
GAA P10253 1/20 0.63
HPGD P15428 1/20 0.63
KDM4E B2RXH2 3/20 0.60
ATM Q13315 2/20 0.60
MAPK1 P28482 2/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
ACP1 P24666 2/20 0.60
NPSR1 Q6W5P4 2/20 0.58
HTT P42858 2/20 0.58
TLR7 Q9NYK1 1/20 0.55
LMNA P02545 3/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 1/20 0.55
METAP1 P53582 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085150 0.89 TLR7 (0.57) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL4097334 0.89 KMT2A (0.61) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL638412 0.85 L3MBTL1 (0.63) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL27492494 0.85 KMT2A (0.64) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL637946 0.83 L3MBTL1 (0.60) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL4084496 0.83 L3MBTL1 (0.60) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL4092351 0.83 NTSR1 (0.58) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL4096964 0.82 MEN1 (0.57) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL460158 0.81 TSHR (0.58) L3MBTL1TSHRGLAHSD17B10GAA
SCHEMBL4089423 0.81 NPY5R (0.59) L3MBTL1TSHRGLAHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 L3MBTL1 3667/4885TSHR 3396/4885GLA 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.